Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2000
Key Event: On September 29, 2000, the Company completed a "pooling of interests" merger with STC Technologies, Inc. and Epitope, Inc. This transaction combined oral fluid collection expertise with up-converting phosphor (UPT) technology. The Company changed its fiscal year-end from September 30 to December 31 effective January 1, 2000.
Key Financial Metrics
| Metric | 2000 | 1999 |
|---|---|---|
| Total Revenues | $28.8 million | $24.0 million |
| Net Loss | $(12.7) million | $(4.2) million |
| Operating Loss | $(14.1) million | $(4.1) million |
| Gross Margin | 61% | 62% |
| Research & Development | $10.4 million | $5.6 million |
| Merger-Related Expenses | $7.6 million | $0 |
| Cash & Short-Term Investments | $20.1 million | $14.3 million |
| Working Capital | $21.5 million | $16.3 million |
| Long-Term Debt | $4.6 million | $5.8 million |
| Accumulated Deficit | $(122.4) million | $(109.6) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 20% to $28.8 million, driven by a 44% increase in oral specimen collection device sales ($11.2 million) and an 18% increase in Histofreezer sales ($6.8 million).
- Expense Surge: Operating expenses rose 53% to $42.9 million. This was primarily due to $7.6 million in non-recurring merger-related costs and an 86% increase in R&D expenses ($10.4 million) focused on OraQuick and UPlink development.
- Product Launches: The Intercept drug testing service and OraQuick HIV-1/2 device began generating revenue in 2000, contributing approximately $300,000 and $80,000 respectively.
- Product Suspension: The Company indefinitely suspended production of the Serum Western Blot product (approx. 5% of 2000 revenue) due to low yields and quality costs.
- Liquidity: Cash and short-term investments increased by $5.7 million to $20.1 million, largely due to $19.8 million in proceeds from stock option and warrant exercises.
Guidance, Outlook, and Risks
- 2001 Outlook: Management expects total revenue to increase 50% to approximately $43 million in 2001. This projection relies on international expansion of OraQuick, the launch of UPlink products in the second half of 2001, and growth in existing lines, partially offset by the loss of Serum Western Blot revenue.
- Profitability: The Company expects to achieve profitability in the second half of 2001, contingent on revenue growth targets and cost savings from manufacturing realignment.
- Manufacturing Realignment: Plans include moving OraQuick manufacturing from Oregon to Pennsylvania and Thailand, expected to save $1.5 million annually starting in 2002.
- Regulatory Risks: The FDA issued observations of deficiencies regarding Good Manufacturing Practices (GMP) at the Oregon facility. While the Company has submitted corrective action plans, failure to satisfy the FDA could halt manufacturing. Additionally, the Company faces patent licensing hurdles for the OraQuick HIV-2 test in certain markets.
- Customer Concentration: LabOne, Inc. accounted for 23% of total revenues in 2000. Loss of this customer could have a material adverse effect.
Investor Verification Checklist
- Merger Integration: Verify the realization of the projected $1 million annual overhead savings and $1.5 million manufacturing savings.
- Regulatory Compliance: Confirm the status of FDA GMP compliance at the Oregon facility and the timeline for full clearance of the Serum Western Blot suspension.
- Product Commercialization: Monitor the FDA clearance status and commercial launch dates for UPlink (drugs-of-abuse) and OraQuick (oral fluid) to validate the 50% revenue growth forecast.
- Patent Licensing: Assess progress in securing necessary licenses for HIV-2 and lateral flow patents to ensure global market access for OraQuick.
- Customer Dependency: Review the stability of the relationship with LabOne, Inc., given its 23% revenue contribution.